Safety analysis of the run-in phase (1st and 2nd cohort) of the IMMUNIB trial (AIO-HEP-0218/ass) - An open-label, single-arm phase II study evaluating safety and efficacy of immunotherapy with nivolumab in combination with lenvatinib in advanced stage HCC
Vogel A, Mueller DW, De Toni E, Siegler GM, Lindig U, Mueller T, Schultheiss M, Geissler M, Krammer-Steiner B, Reichart A, Lammert F, Prause C, Walker M, Al-Batran SE, Kosic N, Siebler J (2020)
Publication Type: Conference contribution
Publication year: 2020
Journal
Publisher: ELSEVIER
City/Town: AMSTERDAM
Pages Range: S691-S691
Conference Proceedings Title: ANNALS OF ONCOLOGY
DOI: 10.1016/j.annonc.2020.08.1104
Authors with CRIS profile
Involved external institutions
HELIOS Kliniken
Germany (DE)
Klinikum Nürnberg
Germany (DE)
Krankenhaus Nordwest
Germany (DE)
Charité - Universitätsmedizin Berlin
Germany (DE)
Friedrich-Schiller-Universität Jena
Germany (DE)
Universitätsklinikum des Saarlandes (UKS)
Germany (DE)
Klinikum Südstadt Rostock
Germany (DE)
Rems-Murr-Kliniken
Germany (DE)
Klinikum Esslingen
Germany (DE)
Albert-Ludwigs-Universität Freiburg
Germany (DE)
Klinikum der Universität München (Großhadern und Innenstadt)
Germany (DE)
Medizinische Hochschule Hannover (MHH) / Hannover Medical School
Germany (DE)
Germany (DE)
Klinikum Nürnberg
Germany (DE)
Krankenhaus Nordwest
Germany (DE)
Charité - Universitätsmedizin Berlin
Germany (DE)
Friedrich-Schiller-Universität Jena
Germany (DE)
Universitätsklinikum des Saarlandes (UKS)
Germany (DE)
Klinikum Südstadt Rostock
Germany (DE)
Rems-Murr-Kliniken
Germany (DE)
Klinikum Esslingen
Germany (DE)
Albert-Ludwigs-Universität Freiburg
Germany (DE)
Klinikum der Universität München (Großhadern und Innenstadt)
Germany (DE)
Medizinische Hochschule Hannover (MHH) / Hannover Medical School
Germany (DE)
How to cite
APA:
Vogel, A., Mueller, D.W., De Toni, E., Siegler, G.M., Lindig, U., Mueller, T.,... Siebler, J. (2020). Safety analysis of the run-in phase (1st and 2nd cohort) of the IMMUNIB trial (AIO-HEP-0218/ass) - An open-label, single-arm phase II study evaluating safety and efficacy of immunotherapy with nivolumab in combination with lenvatinib in advanced stage HCC. In ANNALS OF ONCOLOGY (pp. S691-S691). AMSTERDAM: ELSEVIER.
MLA:
Vogel, A., et al. "Safety analysis of the run-in phase (1st and 2nd cohort) of the IMMUNIB trial (AIO-HEP-0218/ass) - An open-label, single-arm phase II study evaluating safety and efficacy of immunotherapy with nivolumab in combination with lenvatinib in advanced stage HCC." Proceedings of the ESMO Virtual Congress AMSTERDAM: ELSEVIER, 2020. S691-S691.
BibTeX: Download